Clinical TrialJul 10, 2026, 08:06 AM
MIRA Pharma Reports Positive Preclinical MIRA-55 Formulation Results
AI Summary
MIRA Pharmaceuticals announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, its non-opioid drug candidate for chronic inflammatory pain. The company selected a lead formulation demonstrating favorable oral bioavailability, sustained systemic exposure, and reproducible distribution into both brain and liver tissue. These findings strengthen MIRA-55's development profile, building on previous studies that showed it normalized pain and reduced inflammation, outperforming injected morphine, and exhibited a differentiated pharmacological profile from THC.
Key Highlights
- MIRA Pharmaceuticals announced positive preclinical results for optimized oral formulations of MIRA-55.
- A lead oral formulation of MIRA-55 was selected, demonstrating favorable oral bioavailability.
- The lead formulation showed sustained systemic exposure and reproducible distribution into brain and liver tissue.
- These findings strengthen MIRA-55's development profile as a non-opioid therapy for chronic inflammatory pain.
- Previous studies showed oral MIRA-55 normalized pain and reduced inflammation, outperforming injected morphine.
- MIRA-55 exhibited a differentiated pharmacological profile and anxiolytic activity distinct from THC.
- The drug candidate interacts with the cannabinoid system through a mechanism distinct from THC.
Price Impact
More from MIRA